• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Galapagos NV

    4/29/25 4:44:24 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GLPG alert in real time by email
    6-K 1 d902752d6k.htm 6-K 6-K
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 6-K

     

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

     

    For the month of April 2025.

    Commission File Number: 001-37384

     

     

    GALAPAGOS NV

    (Translation of registrant’s name into English)

     

     

    Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium

    (Address of principal executive office)

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

    Form 20-F ☒    Form 40-F ☐

     

     
     


    Annual Shareholders’ Meeting and Extraordinary Shareholders’ Meeting Results

    On April 29, 2025, Galapagos NV (the “Company”) held its Annual Shareholders’ Meeting (the “Annual Meeting”). The minutes and other documentation pertaining to the Annual Meeting can be viewed at https://www.glpg.com/shareholders-meetings within 15 days of the Annual Meeting. The final results of each of the agenda items submitted to a vote of the shareholders at the Annual Meeting are set forth below.

    Annual Meeting Results

    Agenda item 2: acknowledgement and approval of the non-consolidated annual accounts of the Company for the financial year ended on 31 December 2024, and approval of the allocation of the annual result as proposed by the Board of Directors

    The Company’s shareholders’ meeting resolved to approve the non-consolidated annual accounts of the Company for the financial year ended on 31 December 2024, and the allocation of the annual result as proposed by the Board of Directors.

    Agenda item 5: acknowledgement and approval of the remuneration report

    The Company’s shareholders’ meeting resolved to approve the remuneration report included in the annual report of the Board of Directors for the financial year ended on 31 December 2024.

    Agenda item 6: release from liability to be granted to the (current and former) members of the Board of Directors, and the statutory auditor for the performance of their respective mandates during the financial year ended on 31 December 2024.

    The Company’s shareholders’ meeting resolved, by a separate vote, to release each (current and former) member of the Board of Directors, and the statutory auditor from any liability arising from the performance of their respective mandates during the financial year ended 31 December 2024.

    Agenda item 7: appointment of Mr. Oleg Nodelman as non-executive director

    The Company’s shareholders’ meeting resolved, upon proposal of the Board of Directors, and in accordance with the recommendation and advice of the Company’s Nomination Committee, (a) to confirm the appointment by co-optation on October 6, 2024, and with effect as per October 7, 2024, following the resignation of Mr. Daniel Baker on October 6, 2024, and to appoint Mr. Oleg Nodelman as a non-executive member of the Board of Directors of the Company, for an additional period of four years, up to and including the closing of the annual shareholders’ meeting to be held in 2029 which will have decided upon the financial statements for the financial year ended on December 31, 2028. The shareholders’ meeting also resolved that the mandate of Mr. Oleg Nodelman will not be remunerated.

    Agenda item 8: confirmation and appointment of the statutory auditor with respect to the “assurance” of the CSRD sustainability reporting.

    The Company’s shareholders’ meeting resolved, upon proposal of the Board of Directors, in accordance with the recommendation and advice of the Company’s Audit Committee, and taking into account that the Corporate Sustainability Reporting Directive 2022/2464/EU (“CSRD”) in the meantime has been transposed into Belgian law, (a) as far as needed and required, to confirm and ratify the decision by the annual general shareholders’ meeting, which prior to the aforementioned transposition of the CSRD took place on April 30, 2024, to charge the Company’s statutory auditor, being BDO Bedrijfsrevisoren BV, with its registered office at Da Vincilaan 9/E.6, 1930 Zaventem, and registered with the Crossroads Enterprise Database (RPR Brussels, Dutch-speaking division) under the number 0431.088.289, permanently represented by Ellen Lombaerts, for a period of one year, with the assurance of the sustainability reporting of the Company, as referred to in the CSRD, for the financial year ending on December 31, 2024 in accordance with applicable law, (b) taking into account the aforementioned transposition of the CSRD that in the meantime has taken place, to extend the aforementioned mandate of BDO Bedrijfsrevisoren BV for the assurance of the sustainability reporting of the Company, as referred to in articles 3:6/1 - 3:6/8 and articles 3:32/1 - 3:32/6 of the Belgian Companies and Associations Code for a period of one year, to include also the assurance of the sustainability reporting of the Company for the financial year ending on December 31, 2025, so that (taking into account the provisions of article 3:61, §8 of the Belgian Companies and Associations Code) the first term of the statutory mandate of the statutory auditor for the assurance of the sustainability reporting of the Company in accordance with applicable law is aligned with the current mandate of the statutory auditor to audit the Company’s annual financial statement (which shall expire immediately after the annual shareholders’ meeting to be held in 2026), and (c) to determine the remuneration of BDO Bedrijfsrevisoren BV for the assurance of the Company’s sustainability reporting for the financial year ending on December 31, 2025 at EUR 80,000.00 (if any, VAT exclusive). The appointment of the statutory auditor with respect to the aforementioned assurance will expire immediately after the annual shareholders’ meeting to be held in 2026.

    The information contained in this Form 6-K is hereby incorporated by reference into the Company’s Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333-218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756, 333-275886, and 333-283361).


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

         

    GALAPAGOS NV

          (Registrant)
    Date: April 29, 2025      

    /s/ Annelies Denecker

          Annelies Denecker
          Company Secretary
    Get the next $GLPG alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GLPG

    DatePrice TargetRatingAnalyst
    10/22/2025$40.00Market Perform → Outperform
    Leerink Partners
    8/5/2025Hold → Sell
    Deutsche Bank
    2/14/2025$31.00 → $22.00Equal-Weight → Underweight
    Morgan Stanley
    11/20/2024Hold → Reduce
    Kepler
    9/9/2024$24.00Market Perform
    Leerink Partners
    8/2/2024Outperform → Mkt Perform
    Raymond James
    3/28/2024$41.00 → $31.00Neutral → Underperform
    BofA Securities
    3/7/2024$38.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $GLPG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Galapagos NV upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Galapagos NV from Market Perform to Outperform and set a new price target of $40.00

    10/22/25 7:00:32 AM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos NV downgraded by Deutsche Bank

    Deutsche Bank downgraded Galapagos NV from Hold to Sell

    8/5/25 3:22:16 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos NV downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Galapagos NV from Equal-Weight to Underweight and set a new price target of $22.00 from $31.00 previously

    2/14/25 8:06:36 AM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLPG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors

    Mechelen, Belgium; October 23, 2025, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that it will present new in vitro pharmacological data from its selective TYK2 inhibitor, GLPG3667, currently in two Phase 3-enabling studies in dermatomyositis (DM) and systemic lupus erythematosus (SLE), at the American College of Rheumatology (ACR) Convergence 2025, taking place in Chicago, IL, October 24-29, 2025. The data show that the in vitro pharmacological profile of GLPG3667 suggests differentiation from other TYK2 inhibitors at their clinical dose regimens. Key findings from the study include: At exposure levels associated with its clinical dose of 150 mg once daily, GLPG366

    10/23/25 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company's Ongoing Transformation

    Intention follows comprehensive strategic review process and would represent the optimal capital allocation pathway to support a stronger and sustainable future for Galapagos Mechelen, Belgium; October 21, 2025, 07:30 CET; regulated information – inside information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced its intention to wind down its cell therapy business and pursue new transformational business development transactions with its available cash resources. The intention to wind down follows a comprehensive review of strategic alternatives, including a potential divestiture. The plan would enable the Company to enhance operational efficiencies and focus on utilizing its av

    10/21/25 1:30:00 AM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos Announces Appointment of Fred Blakeslee as General Counsel

    Mechelen, Belgium; October 16, 2025, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the appointment of Mr. Fred Blakeslee as Executive Vice President and General Counsel effective October 16, 2025. Blakeslee is succeeding Ms. Valeria Cnossen, who will leave the Company after a short transition period. "We are very pleased to welcome Fred to the executive team," said Henry Gosebruch, CEO of Galapagos. "He brings a unique combination of top-tier legal expertise, global business transaction experience, and deep strategic understanding of the biopharma ecosystem. His proven track record of negotiating complex, high-impact partnerships and acquisitions, and fostering cross-f

    10/16/25 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLPG
    SEC Filings

    View All

    SEC Form 6-K filed by Galapagos NV

    6-K - GALAPAGOS NV (0001421876) (Filer)

    10/24/25 7:14:45 AM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Galapagos NV

    6-K - GALAPAGOS NV (0001421876) (Filer)

    10/21/25 6:05:03 AM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Galapagos NV

    6-K - GALAPAGOS NV (0001421876) (Filer)

    10/16/25 5:06:58 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLPG
    Leadership Updates

    Live Leadership Updates

    View All

    Galapagos Announces Appointment of Fred Blakeslee as General Counsel

    Mechelen, Belgium; October 16, 2025, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the appointment of Mr. Fred Blakeslee as Executive Vice President and General Counsel effective October 16, 2025. Blakeslee is succeeding Ms. Valeria Cnossen, who will leave the Company after a short transition period. "We are very pleased to welcome Fred to the executive team," said Henry Gosebruch, CEO of Galapagos. "He brings a unique combination of top-tier legal expertise, global business transaction experience, and deep strategic understanding of the biopharma ecosystem. His proven track record of negotiating complex, high-impact partnerships and acquisitions, and fostering cross-f

    10/16/25 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Accelerate Business Transformation

    Appoints Sooin Kwon as Chief Business Officer and Dan Grossman as Chief Strategy Officer Both executives possess proven track records in strategic execution and deal-making and will help drive long-term value creation at Galapagos Mechelen, Belgium; July 23, 2025, 22.01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the appointments of Ms. Sooin Kwon as Chief Business Officer (CBO) and Mr. Dan Grossman as Chief Strategy Officer (CStO), effective August 4, 2025, further strengthening the Company's leadership team. They will both report to Henry Gosebruch, CEO, and join the Company's Management Committee. "We are excited to welcome Sooin and Dan to our senior leadership," said

    7/23/25 4:03:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos Welcomes Seasoned Pharmaceutical Executives Dawn Svoronos and Jane Griffiths to Its Board of Directors

    New Directors bring deep commercial, operational, and transaction experience to the Board Mechelen, Belgium; July 23, 2025, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the appointments by way of co-optation of Dawn Svoronos and Jane Griffiths as Non-Executive Independent Directors to its Board of Directors, effective July 28, 2025. Dawn Svoronos and Jane Griffiths will replace Peter Guenter and Simon Sturge, who will step down from the Board on July 28, 2025. Jérôme Contamine, Chair of the Board, said: "We are very pleased to welcome Dawn and Jane to our Board of Directors. Their appointments further strengthen the Board and underscore our commitment to long-term v

    7/23/25 4:02:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLPG
    Financials

    Live finance-specific insights

    View All

    Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts

    First U.S. patient dosed in ATALANTA-1 study of GLPG5101 Mantle cell lymphoma (MCL), a high-unmet-need hematological malignancy, selected as lead indication for the GLPG5101 program; Pivotal development planned to start in 2026 and aiming for approval in 2028 Executive leadership changes with Dr. Paul Stoffels retiring as CEO upon appointment of his successor while continuing as Chair of the Board, Thad Huston departing as CFO/COO on August 1, 2025, and Henry Gosebruch appointed Founding CEO of Galapagos subsidiary SpinCo €3.3 billion in cash and financial investments as of March 31, 2025; Normalized annual cash burn guidance, excluding restructuring costs, in the range of €175 million -

    4/23/25 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update

    Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein Focusing on accelerating GLPG5101 program, expanding to eight indications with significant unmet needs, and aiming for first approval by 2028 Plan to separate into two companies listed on Nasdaq and Euronext, with SpinCo to build a pipeline through deals and Galapagos to advance novel cell therapies for cancers of high unmet need Management to host conference call tomorrow, February 13, 2025, at 14:00 CET / 8:00 am ET Mechelen, Belgium; February 12, 2025, 22:01 CET; regulated information – G

    2/12/25 4:01:00 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities

    Galapagos intends to create a new company with approximately €2.45 billion in cash dedicated to building a pipeline of innovative medicines through transformational transactions Galapagos will gain full global development and commercialization rights to its pipeline, focusing on accelerating cell therapies and building a global, decentralized manufacturing network Galapagos to implement a strategic reorganization to position the Company for long-term growth and cell therapy leadership in oncologyManagement to host conference call today at 14:00 CET / 8:00 am ET MECHELEN, Belgium – January 8, 2025 – 07:30 CET; regulated information – inside information – Galapagos NV ((Euronext &, NASDAQ:GL

    1/8/25 1:30:00 AM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLPG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Galapagos NV

    SC 13G/A - GALAPAGOS NV (0001421876) (Subject)

    11/12/24 9:55:16 AM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Galapagos NV

    SC 13D/A - GALAPAGOS NV (0001421876) (Subject)

    10/8/24 4:35:06 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Galapagos NV

    SC 13D - GALAPAGOS NV (0001421876) (Subject)

    8/23/24 4:01:26 PM ET
    $GLPG
    Biotechnology: Pharmaceutical Preparations
    Health Care